HEPA

Hepion Pharmaceuticals

Delisted

HEPA was delisted on the 12th of May, 2025.

1 hedge funds and large institutions have $3.16M invested in Hepion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
% of All Funds
0.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Shares
Change %
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.63M +$1.63M +1 New
Morgan Stanley
2
Morgan Stanley
New York
$708K -$277K
BFA
3
BlackRock Fund Advisors
California
$315K
Geode Capital Management
4
Geode Capital Management
Massachusetts
$131K
EVC
5
Eidelman Virant Capital
Missouri
$76K
PFS
6
Prospera Financial Services
Texas
$69K
CS
7
Credit Suisse
Switzerland
$61K
CC
8
Callan Capital
California
$52K -$31K
Deutsche Bank
9
Deutsche Bank
Germany
$26K -$15K
BIM
10
BlackRock Investment Management
Delaware
$19K
BIT
11
BlackRock Institutional Trust
California
$19K
BA
12
BlackRock Advisors
Delaware
$19K
Wells Fargo
13
Wells Fargo
California
$18K -$11K
VIA
14
Vantage Investment Advisors
Pennsylvania
$5K -$3K
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$3K -$2K
AIG
16
American International Group
New York
$1.44K -$872
Bank of America
17
Bank of America
North Carolina
$1K
CA
18
CapWealth Advisors
Tennessee
$1K -$1K
CAL
19
Capital Advisors Ltd
Ohio
$1K -$1K
Manulife (Manufacturers Life Insurance)
20
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1 -$1
UBS Group
21
UBS Group
Switzerland
-$2K
Barclays
22
Barclays
United Kingdom
-$1K
TDC
23
Thompson Davis & Co
Virginia
-$2K
TRCT
24
Tower Research Capital (TRC)
New York
-$3K
SIM
25
Spark Investment Management
New York
-$40K